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Profiling walking dysfunction in 
multiple sclerosis: characterisation, 
classification and progression over 
time
Linard Filli  1, Tabea Sutter1, Christopher S. Easthope2, Tim Killeen  2, Christian Meyer2, 
Katja Reuter1, Lilla Lörincz1, Marc Bolliger2, Michael Weller1, Armin Curt2, Dominik 
Straumann1, Michael Linnebank1,3 & Björn Zörner1,2
Gait dysfunction is a common and relevant symptom in multiple sclerosis (MS). This study aimed 
to profile gait pathology in gait-impaired patients with MS using comprehensive 3D gait analysis 
and clinical walking tests. Thirty-seven patients with MS walked on the treadmill at their individual, 
sustainable speed while 20 healthy control subjects walked at all the different patient’s paces, allowing 
for comparisons independent of walking velocity. Kinematic analysis revealed pronounced restrictions 
in knee and ankle joint excursion, increased gait variability and asymmetry along with impaired 
dynamic stability in patients. The most discriminative single gait parameter, differentiating patients 
from controls with an accuracy of 83.3% (χ2 test; p = 0.0001), was reduced knee range of motion. Based 
on hierarchical cluster and principal component analysis, three principal pathological gait patterns were 
identified: a spastic-paretic, an ataxia-like, and an unstable gait. Follow-up assessments after 1 year 
indicated deterioration of walking function, particularly in patients with spastic-paretic gait patterns. 
Our findings suggest that impaired knee/ankle control is common in patients with MS. Personalised gait 
profiles and clustering algorithms may be promising tools for stratifying patients and to inform patient-
tailored exercise programs. Responsive, objective outcome measures are important for monitoring 
disease progression and treatment effects in MS trials.
Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS leading to demyelination of fibres and neu-
ronal degeneration. MS is the leading cause of progressive functional impairment in young adults1. Three of four 
people with MS report reduced mobility due to impaired walking function at some point during their lifetime2,3. 
Walking impairment is perceived as the most restricting of symptoms by patients and constrains quality of life4–6.
Walking abnormalities in patients with MS are, nevertheless, poorly characterised. MS-related lesions may 
be widely disseminated throughout the brain and spinal cord, leading to a variety of gait abnormalities including 
ataxia, muscular weakness and spasticity-related signs7–9. Accordingly, there is no widely-accepted, typical gait 
pattern in MS unlike in other neurological disorders such as Parkinson’s disease or after unilateral cerebral stroke. 
Previous studies assessing gait deviations in patients with MS described reduced gait speed and step length7,9–14, 
reduced range of motion (ROM) of leg joints7,12,15,16, increased double-limb support7,10,17, and reduced dynamic 
stability17. In the aforementioned studies, however, patients and healthy controls walked at their respective 
self-selected speed, resulting in significant speed differences between groups. As the vast majority of locomotor 
parameters is strongly influenced by gait velocity18, slower walking speed in patients relative to controls is a major 
confounder, limiting the characterisation of MS-related gait pathophysiology9,19,20.
While several studies performed cross-sectional characterisation of walking dysfunctions in patients with MS, 
longitudinal assessments of the decline in walking performance in patients are rare21–23. However, monitoring 
of disease progression and walking dysfunction over time is important in the clinical setting, as it may help to 
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adjust and optimise treatment strategies over the course of the disease24. Further, accumulative walking impair-
ment is a hallmark of secondary progressive MS25 and changes in walking function based on detailed, reliable 
and quantitative assessments may serve as objective surrogate marker for conversion from relapsing-remitting 
to secondary-progressive MS. Comprehensive profiling of walking deficits, ranging from personalised gait sig-
natures to objective cluster analysis of locomotor patterns, may help in monitoring therapies aimed at restoring 
walking function in patients and to identify sensitive endpoint measures for future trials in MS.
In this study, we characterised multiple sclerosis-related gait pathology, aimed at detecting and defining char-
acteristic gait patterns in patients, and monitored deterioration of walking function over a period of one year.
Results
Study population. Thirty-seven patients with MS (48.6 ± 10.3 years; 24 female) and 20 able-bodied, 
healthy controls (48.8 ± 10.1 years; 12 female) were included (Table 1). Eleven of 37 patients used walking aids 
at least occasionally during everyday life. Demographic data of patients were not different from healthy subjects 
(Table 1). Ambulatory performance in clinical walking tests including maximal walking speed in the T25FW and 
endurance in the 6MWT were significantly reduced in patients (T25FW: −72%; 6MWT: −44%; p < 0.0001 for 
both tests; two-tailed, unpaired t-test; Table 1).
Impact of walking speed on kinematic gait parameters. vmax50 was higher in healthy controls 
(1.08 ± 0.12 m/s) than in patients (0.64 ± 0.17 m/s; p < 0.0001, two-tailed, unpaired t-test; Supplementary 
Table S1). As previously reported by others18,20,26, we found that most kinematic gait parameters changed signif-
icantly with walking speed (Supplementary Table S1) demonstrating that differential walking speeds in patients 
and healthy controls confound the precise characterisation of walking deficits.
Characterisation of walking impairments in patients with MS. Patients showed a bilateral reduction 
in step length, which was associated with diminished ROM in the leg joints (Fig. 1). While ROM of the hip was 
preserved, significant reductions in the extent of movement were observed at the knee in particular, but also at 
the ankle joint. The more pronounced restriction of ROM at the knee and ankle joint of the weakest leg resulted 
in substantial left-right asymmetry. Mid-swing toe clearance in the strongest leg was increased, while the length 
of the wrist movement trajectory ipsilateral to the weakest leg was increased by more than 30% (Fig. 1). Most 
markers of dynamic instability such as step width (+49%), upper trunk movement (C7 trajectory: +17%) and 
the mediolateral (+25%) and anteroposterior (+43%) components of the centre of mass (COM) trajectory were 
increased in patients. Gait variability was strongly increased in patients while parameters of inter-limb coordina-
tion and stance phase duration only showed minor deviations in patients (Fig. 1 and Supplementary Table S1).
We also investigated curve progressions of leg joint angular excursions over the entire gait cycle in controls 
(n = 20) and patients (n = 28) walking at a fixed speed of 2 km/h (Fig. 2). Hip angles of the patients’ weakest leg 
revealed a subtle shift of 5 degrees towards extension (Fig. 2C,D). Stick figures and angle plots demonstrated 
patients healthy controls P-values
number of participants 37 20
age [y] 48.6 ± 10.3 48.8 ± 10.1 0.9286
female [%] 24/37 12/20 0.7780
height [cm] 170.4 ± 9.9 170.9 ± 7.0 0.4642
weight [kg] 68.5 ± 17.1 71.7 ± 11.5 0.8600
disease type: RRMS/PPMS/SPMS 22/2/13
disease duration [y] 10.7 ± 6.9
T25FW [s] 6.2 ± 2.7 3.6 ± 0.4 <0.0001
6mWT [m] 397.0 ± 116.0 709.9 ± 74.7 <0.0001
EDSS [pts] 4.5 ± 1.0
manual muscle testing:
hip flexion (w/s) 4.39/4.69 5/5
knee flexion (w/s) 4.39/4.87 5/5
knee extension (w/s) 4.74/4.93 5/5
ankle extension (w/s) 4.47/4.87 5/5
DMT of multiple sclerosis
(number of patients)
interferon 6
fingolimod 4
natalizumab 12
no treatment 15
Table 1. Demographic data of patients and healthy control subjects. For statistical analysis, two-tailed, 
unpaired t-test or Fisher’s exact test was used. Abbreviations: EDSS: Expanded Disability Status Scale; DMT: 
disease-modifying treatment; PPMS: primary progressive MS; RRMS: relapsing remitting MS; SPMS: secondary 
progressive MS; s: strongest leg; T25FW: Timed-25 foot walk; w- weakest leg; 6MWT: 6-minute walk test.
www.nature.com/scientificreports/
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the reduced knee flexion in patients, mainly in the weakest leg (red) during swing phase (Fig. 2B–E). Angular 
excursion of the ankle joint showed a decrease in ankle dorsiflexion of the weakest leg during stance and swing 
phase (Fig. 2C,F). Analysis of leg end-point control (toe trajectory) revealed reduced and delayed toe clearance in 
patients during early swing phase (Fig. 2G,H), possibly due to the delayed initiation of knee flexion at pre-swing 
(Fig. 2E). Patients’ toe height was increased during mid-swing but reduced at heel-strike, the latter indicating 
impaired foot roll dynamics (Fig. 2F–H). Intra-limb joint coordination revealed similar cyclogram shapes in 
patients and controls indicating preserved temporal coupling of leg joints (Fig. 2I,J). Differences in the size of the 
cyclograms were mainly due to pathological changes in knee and ankle ROM.
Binary logistic regression analysis of kinematic data (Fig. 2) revealed that the best indicator of pathological 
gait was knee ROM of the weakest leg, achieving an accuracy of 83.3% in classifying patients with MS and healthy 
participants (χ2 test: p = 0.0001).
Individual gait signatures in patients with MS. Detailed gait profiles were generated for each patient to 
uncover individual deficits of walking function (Fig. 3). At each walking speed and parameter, the mean value ± 2 
Figure 1. Characterisation of MS-related gait pathology based on 28 key walking parameters. Gait markers of 
limb excursion (salmon pink), parameters of range of motion (blue), asymmetry (purple), stability (turquoise) 
and variability (dark blue) revealed substantial changes of walking pattern in patients with MS (n = 37) walking 
at half-maximal gait speed (vmax50%) compared to normative data obtained from 20 healthy control participants 
walking at identical speeds. Bars represent mean values ± SEM. Abbreviations: ASI: asymmetry index; AP: 
anteroposterior; COM: centre of mass; COV: coefficient of variation; disp.: dispersion; DLS: double-limb 
support; il. coord.: inter-limb coordination; strong: strongest leg; weak: weakest leg; ML: mediolateral; ROM: 
range of motion; traj.: trajectory.
www.nature.com/scientificreports/
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standard deviations measured in 20 control subjects was defined as the normal range (Fig. 3B). Values above or 
below this range were defined as pathological (Fig. 3A). The general distribution of the individual, pathological 
changes reflected the findings at the group-level (Figs 1, 2), for example, reduced step length and ROM of the 
more distal leg joints (Fig. 3A). Individual gait profiles also exposed a degree of heterogeneity in walking patterns, 
for instance, patients with pronounced reductions in distal leg joint excursions (014) or with a more unstable and 
variable walking pattern (023).
Classification of predominant walking patterns in MS. Hierarchical cluster analysis was used to iden-
tify the main patterns of walking dysfunction in PwMS. In a first step, the clustering algorithm was validated with 
a dataset consisting of 28 gait parameters assessed in 20 healthy participants and 28 patients walking at 2 km/h. 
The algorithm demonstrated 93.8% accuracy in distinguishing between patients and healthy controls. We then 
used the same algorithm to identify the prevailing gait patterns in the main cohort of patients (n = 37) walking 
at vmax50% and identified three different gait patterns (Fig. 4). PCA revealed group data clouds that were largely 
separated in the PC space, thus confirming differential walking patterns of the three identified cluster subgroups 
(Fig. 4A). Subgroup 1 was characterised by a particularly marked reduction in knee ROM and increased left-right 
knee asymmetry, but little impairment in dynamic stability and gait variability. Subgroup 2 revealed increased toe 
height at mid-swing with strongly enhanced gait variability, but with relatively well-preserved walking stability 
and symmetry. In contrast, subgroup 3 demonstrated pronounced dynamic instability with less-impaired joint 
Figure 2. Temporal and spatial deviations in gait pattern of patients with MS compared to controls. Both 
patients and controls walked at a fixed speed of 2 km/h. (A) Schematic illustration of stick figure and marker 
position overlying anatomical landmarks. (B) Average stick figures of healthy participants (n = 20; black) and 
patients (n = 28; strongest leg (blue); weakest leg (red)) during stance and swing phase. (C) Statistical analysis 
(two-way ANOVA repeated measures) depicting periods (gait phases; left) and p-values (right) of significant 
differences between angular hip, knee and ankle excursions of patients (strongest and weakest leg) and healthy 
controls (see D–F). (D–F) Hip, knee and ankle angular excursions ± SEM during an averaged step cycle (groups 
and colors as in B; grey dashed line indicates toe-off). (G) 2-dimensional toe trajectory illustrating the sagittal 
movement pattern of the lower extremity endpoint (groups and colors as in B). (H) Toe clearance during swing 
phase (groups and colors as in B). (I, J) Angle-angle plots (cyclograms) depicting intra-limb coordination of 
the hip, knee and ankle during stance (straight line) and swing phase (dashed line) (groups and colors as in B). 
Abbreviations: deg: degrees; strong: strongest leg; weak: weakest leg; ROM: range of motion.
www.nature.com/scientificreports/
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excursions, in particular at the ankle (Fig. 4B). ReliefF feature selection analysis confirmed the main relative dis-
criminants identified in the cluster and PC analysis (Fig. 4C).
The EDSS step was not different between the three cluster subgroups (Fig. 4D; 1-way ANOVA). However, 
pyramidal dysfunction scores were higher in subgroup 1 (Fig. 4D; pyramidal vs. cerebellar: p = 0.0115; pyramidal 
vs. sensory: p = 0.0016; 1-way ANOVA, repeated measures), whereas subgroup 2 showed a trend towards more 
pronounced cerebellar deficits. Walking performance in clinical walking tests and muscle strength of the differ-
ent leg muscle groups (LEMMT) were not different between the three cluster subgroups (Supplementary Fig. S1; 
1-way ANOVA; 2-way ANOVA, repeated measures, respectively). Proportions of concomitant MS therapies were 
not different between the cluster groups (p = 0.656; χ2 test).
Decline of waking function in patients with MS over 1 year. Twenty-nine of 37 patients were avail-
able for follow-up assessment, with eight patients declining further participation in the study. Demographics 
of the remaining patients were statistically not different from the baseline cohort and the healthy control group 
(two-tailed, unpaired t-test or Fisher’s exact test). Two participants experienced a clinically-apparent relapse 
between baseline and follow-up assessments, but none were in an active relapse phase during measurements. 
Proportions of concomitant MS therapies were not different between the cluster groups (p = 0.935; χ2 test). 
Only 2 of 29 patients revealed changes in concomitant MS treatment over 1 year. Kinematic analysis after 1 year 
revealed subtle but significant differences in walking patterns over time. Most gait parameters remained similar 
over 1 year. The only significant change in gait kinematics concerned an increasing impairment in knee joint 
excursions (knee ROM of strongest leg; p = 0.0129; two-tailed, paired t-test; Fig. 5A). Knee ROM worsened in 
21 of 29 patients, both in the weakest and strongest leg, resulting in a bilateral reduction of ROM of around 6% 
Figure 3. Individual gait profiles of patients with MS. (A) Kinematic gait parameters for single subjects with 
MS (n = 37) walking at half-maximal gait speed (vmax50%) represented in a color-coded grading system. Twenty-
eight parameters were classified as normal/unchanged (grey), pathologically reduced (blue) or pathologically 
increased (red) based on normative data obtained from 20 healthy controls. (B) Graphs show changes in 
selected gait parameters in subjects with MS in relation to walking speed. Values located outside the interval 
of the mean ± 2 SD of 20 healthy control subjects (dashed grey line) were defined as pathological. Data for 
the weakest leg is displayed in red, while values for the strongest leg are shown in blue. Abbreviations: AP: 
anteroposterior; ASI: asymmetry index; COM: centre of mass; COV: coefficient of variation; disp.: dispersion; 
deg: degrees; DLS: double-limb support; il. coord.: inter-limb coordination; s: strongest leg; MdS: midswing; 
ML: mediolateral; Pat. ID: patient identification number; ROM: range of motion; SD: standard deviation; traj.: 
trajectory; w- weakest leg.
www.nature.com/scientificreports/
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Figure 4. Kinematic gait patterns of three subgroups of patients with MS as identified by hierarchical cluster 
analysis. Gait parameters were assessed at patients’ half-maximal walking speed (vmax50%) (A) Principal 
component analysis (PCA) visualizing the locomotor pattern of the three cluster subgroups (group 1: n = 16; 
green; group 2: n = 12; red; group 3: n = 9; black) in the 3-dimensional PC space. Graphs on the right show 
mean scores on PC1–3 for all three cluster subgroups. Asterisk indicates statistically significant differences 
(p < 0.05) between PCs for different cluster subgroups as revealed by 1-way ANOVA repeated measures with 
post hoc correction for multiple testing. Variables showing the highest factor loading on PC1, PC2 and PC3 (i.e. 
correlation between each variable and PC space) are depicted (right low corner). (B) Gait profiles of the three 
cluster subgroups based on single kinematic parameters. Dots represent group mean values ± SEM for each 
cluster subgroup. Asterisk indicates statistically significant differences between subgroups as analysed by 1-way 
ANOVA repeated measures followed by post hoc correction for multiple comparisons (*p < 0.05/28 = 0.0018). 
(C) ReliefF feature selection algorithm was used to quantify the importance of predictors (IoP) to distinguish 
the different cluster groups of specific kinematic parameters (D) Expanded Disability Status Scale scores for 
the different cluster subgroups (group 1: green; group 2: red; group 3: black). Asterisk indicates statistically 
significant differences between groups as revealed by 1-way ANOVA repeated measures (*p < 0.05; **p < 0.01). 
Data are presented as mean ± SEM. Abbreviations: AP: anteroposterior; ASI: asymmetry index; COM: centre 
of mass; COV: coefficient of variation; disp.: dispersion; DLS: double-limb support; EDSS: Expanded Disability 
Status Scale; interl.coord.: inter-limb coordination; s: strongest leg; ML: mediolateral; w- weakest leg; PC: 
principal component; ROM: range of motion; SD: standard deviation; traj.: trajectory.
www.nature.com/scientificreports/
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over a period of 1 year (Fig. 5B). Clinical walking tests demonstrated significantly diminished walking endurance 
in patients after 1 year (−6.5% or −27.1 m in the 6MWT; p = 0.0027; two-tailed, paired t-test; Fig. 5D). Walking 
decline was pronounced in cluster subgroup 1 (T25FW: p = 0.0473; 6MWT: p = 0.0258; 2-way ANOVA, repeated 
measures; Supplementary Fig. S1). Interestingly, deterioration in knee ROM over time correlated with the decline 
in walking function in the T25FW (R = 0.421; p = 0.023; Pearson correlation) and 6MWT (R = 0.407; p = 0.029). 
The total EDSS step and its functional system subscores did not change over 1 year in our patient cohort (Fig. 5E; 
two-tailed, paired t-tests).
Discussion
We prospectively characterised gait deficits in a cohort of 37 patients with MS applying sensitive, state-of-the-art 
3D-kinematic gait analysis during treadmill walking and classified these patients into three different subgroups 
based on their walking pattern. We demonstrate mild, but significant, deterioration of walking function over a 
period of 1 year. Locomotor profiles were supplemented by neurological examination and clinical, overground 
walking tests.
Figure 5. Monitoring kinematic gait parameters and clinical walking performance in patients with MS over 
a period of 1 year. Gait analysis in patients (n = 29) was performed at baseline and 12 months later at identical 
walking speeds (vmax50%). (A) Gait profiles including 28 kinematic parameters with darker colors representing 
parameter values at baseline and brighter colors indicating values at the 1-year follow-up assessment. Bars 
represent mean ± SEM. Statistical analysis was performed by two-tailed, paired t-test followed by post hoc 
correction for multiple testing. Asterisk indicates p-value below the adjusted level of significance (α = 0.05/28). 
(B) Changes of individual patients’ knee ROM over 1 year for the weakest and strongest leg. Group mean 
changes in knee ROM between baseline and follow-up measurements are highlighted in red numbers. (C) 
Maximal walking speed (assessed with the timed 25-foot walk) was not significantly different, whereas (D) 
walking endurance (measured with the 6-minute walk test; 6MWT) showed a significant decline over time. 
Statistical significance was assessed by two-tailed, paired t-test. (E) Longitudinal assessment of the EDSS step 
and the functional system scores (pyramidal, cerebellar and sensory) did not reveal any significant differences 
over 1 year (two-tailed, paired t-test). Abbreviations: AP: anteroposterior; ASI: asymmetry index; COM: centre 
of mass; COV: coefficient of variation; disp.: dispersion; DLS: double-limb support; EDSS: Expanded Disability 
Status Scale; FS: functional system; cer: cerebellar; interl.coord.: inter-limb coordination; strong: strongest leg; 
ML: mediolateral; weak: weakest leg; pyr: pyramidal; ROM: range of motion; SD: standard deviation; sens: 
sensory; traj.: trajectory; T25FW: Timed 25-foot walk; v50%: half-maximal walking speed; y: year; 6MWT: 
6-minute walk test.
www.nature.com/scientificreports/
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In contrast to most cross-sectional comparative studies in this field of research7,12,17, the present study per-
formed gait analysis beyond standard spatio-temporal walking parameters and generated full-body gait profiles 
based on a comprehensive set of upper and lower extremity and trunk kinematic parameters. Previous key studies 
describing gait abnormalities in patients with MS used participants’ freely-chosen walking speeds, resulting in 
paces that were typically reduced by 30–40% in patients compared to healthy controls7,9,11,12,16,27. We confirm that 
most walking parameters scale with walking speed and, therefore, conclude that accurate comparison of walking 
patterns between patients and healthy controls critically requires identical walking speeds. Thus, heterogeneous 
walking speeds in prior studies investigating walking deficits in MS likely explain some inconsistent results7,12,17. 
However, assessing gait while allowing patients to walk at their preferred speed is widespread due to its relevance 
to everyday life and the different demands placed on maintaining body control at slower vs. faster speeds28. To 
solve this problem, we compared each patient walking at a sustainable, moderate speed with 20 speed-matched 
controls for a more conclusive characterisation of gait impairments in MS.
In line with previous reports, we found reduced knee and ankle joint excursions in subjects with MS12,20. In 
contrast to earlier reports, however, we demonstrated that hip joint excursions and inter- and intra-limb coor-
dination were barely affected in patients. Basic human and animal research suggests that these latter functions 
are primarily controlled by spinal interneuron networks known as central pattern generators (CPGs). The CPG 
networks are modulated by supraspinal and sensory drive but can also act independently of descending input29–32. 
In contrast, the strongly-affected distal limb control, including knee and ankle movements, as well as fine adjust-
ments in foot positioning during walking to ensure dynamic stability, is thought to rely more heavily on the 
integrity of cortical, cerebellar and brainstem systems with their long descending and ascending myelinated fibre 
tracts33–35. The pattern of functional impairment described above may be explained by the common sites of MS 
lesions and resulting axonal loss and neurodegeneration within the CNS of PwMS: lesions are less pronounced 
in spinal grey than white matter and there seems to be a predilection for involvement of the long descending and 
ascending fibre tracts in comparison to spinal interneuron circuits such as CPGs36,37. These concepts should be 
further investigated using magnetic resonance imaging to assess correlations between lesioned CNS structures 
and the resulting functional impairments. The walking pattern of patients with MS described here is different 
from other neurological conditions such as that seen in Parkinson’s disease38 or patients with incomplete spinal 
cord injury, with the latter showing increased hip angular excursion in the context of unaltered knee angular 
excursion compared to controls walking at the same speed39.
Of all gait parameters evaluated in this study, impaired knee flexion was one of the main kinematic features of 
MS gait reaching an accuracy of 83% in differentiating gait patterns of patients from controls40. This is in line with 
previous studies reporting that impaired knee flexion is an important MS-associated gait characteristic and a valid 
predictor of walking function/gait speed in these patients41,42. Intriguingly, improved knee flexion as induced by 
pharmacological agents (fampridine40, baclofen43), or with functional electrical stimulation44 or physical exer-
cise43,45 have previously been associated with enhanced walking function in PwMS. Restoring knee excursion thus 
seems to be a promising approach for future treatment options aiming at improving walking function in PwMS46.
Using cluster and principal component analyses, we identified three subgroups in our patient cohort walking 
with distinctive gait patterns. The first subgroup was characterised by a pronounced reduction of knee ROM (par-
ticularly during swing phase), resulting in increased left-right asymmetry, and also decreased excursions in the 
ankle joints, while other aspects of walking function were largely preserved in these patients. This walking pattern 
may correspond most closely to a “spastic-paretic” gait as reported for patients with spastic hemi-/paraparesis47,48, 
in line with the clinical finding that these patients primarily presented with signs of pyramidal dysfunction. To 
what extent the reduced knee ROM during swing phase is caused by paresis (e.g. hamstrings), increase of mus-
cle tone (e.g. rectus femoris) or decreased push-off power in the ankle joint (e.g. gastrocnemius) remains to be 
investigated in future studies49. Reduction of knee flexion strength in the weakest leg as assessed with BMRC 
manual muscle testing was not more pronounced for this subgroup of patients compared to cluster groups 2 and 
3 (p = 0.8458). However, the ability of such static manual muscle testing to reliably reflect muscle function during 
dynamic conditions is disputed50. Reliable quantification of spasticity remains difficult and, therefore, was not 
considered in the present study51–54.
The most striking characteristic of the second subgroup was increased spatial variability of leg and trunk 
movements accompanied by increased toe height during mid-swing phase. Strongly increased gait variability is 
a cardinal feature in patients with sensory or cerebellar gait ataxia55–60. However, there was only a trend towards 
a more impaired cerebellar function in the clinical examination in these patients with an ataxia-like walking pat-
tern. Increased toe height may serve as compensatory strategy to prevent tripping or falling in these patients55,61.
The third subgroup was mainly characterised by increased dynamic instability as evident by a broad-based 
gait and excessive trunk movements, both in the mediolateral and anteroposterior direction. Interestingly, these 
patients demonstrated increased ROM in their ankle joints, which may be considered a strategy to counteract 
impaired balance control62 or, in contrast, may reflect deficient ankle joint stabilization during walking. Postural 
instability appears to be a non-specific symptom that can be found in many neurological disorders including 
stroke, cerebellar disorders, traumatic brain injury and Parkinson’s disease63–67.
Stratifying patients with MS into different “functional” subgroups based on objective and comprehensive 
gait assessments may open new avenues for therapeutic approaches and may be important in the targeting of 
patient-tailored rehabilitative training programs. Also, disease progression may be different between subgroups; 
in our cohort, patients in subgroup 1 demonstrated the most marked deterioration of walking performance in the 
clinical walking tests over 1 year.
MS is a progressive disease and persisting functional deficits are thought to be primarily related to neuro-
degenerative processes during the advanced stages of the disease68. While the EDSS did not capture neurolog-
ical decline in our cohort of patients, clinical walking tests and kinematic gait analysis demonstrated sufficient 
responsiveness to detect worsening of walking function over 1 year. Whereas changes in the T25FW (+3.2% or 
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+0.18 s) were small and did not reach the threshold for clinically meaningful changes (≥20% improvement)69,70, 
deterioration in the 6MWT (−6.5% or −27.1 m) were significant and reached the threshold that has previously 
been associated with clinically meaningful changes in PwMS (>21.6 m)71. Walking deterioration in our cohort 
was slightly more pronounced when compared to an earlier report examining walking function of 109 PwMS 
over 2 years23. Specifically, gait analysis revealed deterioration of one key parameter of gait dysfunction in MS 
over time, namely ROM of the knee joint. The clinical relevance of this kinematic finding was supported by a cor-
related decline in performance in clinical walking tests. These results highlight the value of clinical walking tests 
as outcome measures for monitoring walking function and disease progression over time while also confirming 
the role of kinematic gait analyses in identifying the mechanisms underlying gait disturbances in MS72.
One limitation of the present study is that only patients able to walk without assistance on the treadmill were 
included, as the use of handrails during treadmill walking has a profound effect on gait patterns and obscures 
walking impairments73. The present results may therefore not be applicable to the full spectrum of MS-related gait 
disorders. However, one third of our patients used walking aids at least occasionally in everyday life, indicating 
that our population also included patients with notable walking deficits. Our data were performed during tread-
mill walking and thus might not completely reflect spontaneous, everyday, overground walking. However, a sub-
stantial amount of literature supports the conclusion that the basic biomechanics of treadmill walking are highly 
similar to overground walking given sufficient acclimatisation to treadmill walking prior to gait analysis74–77. 
Moreover, the sample size of this study is limited (mainly for measurements assessing walking deterioration) and 
results need to be confirmed in larger cohort studies.
To conclude, gait disturbances in a cohort of mildly- to moderately-affected patients with MS are typified by 
decreased knee and ankle flexion, reduced dynamic stability and increased variability of movements. Subgroup 
analysis highlighted three dominant walking patterns in these patients: spastic-paretic gait, ataxia-like gait and 
unstable gait. While sensitive kinematic gait analysis and clinical walking tests detected deterioration of walking 
function over 1 year, EDSS scores did not reveal any change in our cohort. These insights may help to inform 
rehabilitative gait training in patients and to develop deficit-specific and patient-tailored exercise programs.
Materials
Participants. Thirty-seven patients diagnosed with relapsing-remitting, primary- or secondary-progres-
sive MS and clinical walking impairment were assessed at University Hospital Zurich between 2012 and 2013 
(FAMPKIN study; clinicaltrials.gov, NCT01576354). For inclusion, patients had to be able to cover a distance of 
at least 50 meters within 6 minutes and to walk independently on an instrumented treadmill. Healthy control par-
ticipants were measured within the framework of a two-centre study (University Hospital Zurich and University 
Hospital Balgrist). Both studies were approved by the Zurich cantonal ethics committee (KEK-2011-0445, KEK-
2014-0004) and were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. All 
subjects gave written, informed consent.
Study design and experimental procedures. All participants underwent a neurological examination 
including the Expanded Disability Status Scale (EDSS)78, the Lower Extremity Manual Muscle Test (LEMMT)79, 
the timed 25-foot walk (T25FW)80 and 6-minute walk test (6MWT)81. The maximal overground walking speed 
(vmax100%) was determined from the T25FW and 50% of this speed (vmax50%) was set as proportional walking speed 
on the treadmill for each patient. This approach allows direct comparison between patients with varying degrees 
of walking impairment and healthy controls and participants. The resulting treadmill speed is a moderate, sus-
tainable walking velocity universally reported to be comfortable for treadmill walking by patients82. As such, we 
refer to vmax50% as a “sustainable” speed in this manuscript. Twenty healthy participants walked at different speeds 
ranging from 0.4 to 3.1 km/h (in intervals of 0.3 km/h) to match the individual walking speeds of all patients. 
All participants underwent an extensive acclimatisation protocol (≥15 minutes) to familiarise themselves with 
treadmill walking, as basic locomotor patterns on the treadmill approach spontaneous overground walking only 
in subjects well familiarised to treadmill walking74,77,83. Analysis of angular curves and cyclograms was conducted 
at a fixed speed of 2 km/h for all participants, as only an identical speed allows for a direct comparison/illustration 
of kinematic parameters in patients and controls. All other kinematic data of this paper are based on patients 
walking at their individual, sustainable speed (vmax50%) as described above. In follow-up assessments after 12 
months, patients again underwent kinematic gait analysis (while walking at vmax50%) and clinical walking tests. All 
patients received treatment with prolonged-release fampridine within the framework of the FAMPKIN study40,84. 
However, treatment was discontinued 14 days before measurements.
Three-dimensional gait analysis was performed while participants walked barefoot for at least 30 seconds 
per trial on an instrumented treadmill (120 Hz, FDM-T, Zebris Medical GmbH, Germany) in a gait laboratory 
equipped with 14 infrared cameras recording via Nexus 2.2.3 (Vicon, Oxford, UK) motion capture software at a 
sampling rate of 200 Hz. Twenty-nine reflective markers (14 mm diameter) were placed on the skin based on the 
full-body gait model (Plug-in-Gait, Vicon, UK). Reflective markers were always placed by the same experienced 
physiotherapist and were visually inspected by a second team member, while the subject was in a standing posi-
tion at full leg extension.
Gait parameters and data analysis. Data were processed in Nexus 2.2.3 and parameters were extracted 
using ProCalc (Vicon, Oxford, UK) analysis software. Gait events were defined by zero-crossings in toe marker 
velocity as described previously40,85. The strongest and weakest leg of each patient was defined based on the neu-
rological examinations. We quantified 28 key gait parameters describing leg, trunk and arm movements to com-
prehensively characterise walking patterns in patients and healthy controls. Gait parameters were assessed per 
step cycle and were classified into different functional domains: (1) limb excursion: step length, toe height at 
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mid-swing phase, 3D path of wrist trajectory; (2) range of motion: range of motion (ROM) of hip, knee and ankle 
joints (leg joint angles were calculated by a 3D vector-based approach described elsewhere86; (3) asymmetry: 
left-right asymmetry of leg joint excursion as assessed by a modified asymmetry index (ASI; see equation (1)) 
used elsewhere87,88:
= − ×ASI ((left right)/(max) (left, right)) 100 (1)
(4) instability: step width, 3D path of cervical spine (C7) marker, centre of mass (COM) movements in mediolat-
eral (ML) and anteroposterior (AP) directions; (5) inter-limb coordination: temporal left–right coordination of 
legs and arms as defined by phase dispersion89,90. In a subject walking perfectly in phase, heel strike of one limb 
occurs precisely at the mid-point of the contralateral step cycle, resulting in a phase dispersion of 0.5. (6) gait 
phases: stance phase, double-limb support (DLS); (7) variability: coefficient of variation (COV) of step length, 
step width and C7 marker trajectory.
Statistical analysis. Statistical analysis was performed using SPSS (V23, SPSS Inc., CA, USA), Matlab 
(Mathworks, Inc., USA) and Graphpad Prism 7 (GraphPad Software, Inc., CA, USA). The applied parametric 
tests are described in the respective figure legends. The level of significance was set at 0.05. All statistical tests were 
adjusted for multiple comparisons via post-hoc Bonferroni correction. Personalised gait profiles (Fig. 3) were 
developed based on contrasts relative to the distribution of specific gait parameters in healthy subjects91. Binary 
logistic regression (Wald forward stepwise) was used to discover the principal gait parameters distinguishing gait 
patterns of patients from healthy control participants.
Hierarchical cluster analysis was performed using Ward’s method, described as particularly robust in identi-
fying functional patterns92. Variables were z-standardised and the Euclidian distance used as measure of dissim-
ilarity93,94. The optimal number of clusters was determined by the R ratio, a measure of intra-cluster variability. 
A threshold value of R > 15 was applied, similar to approaches used previously to identify differential patterns94. 
Key attributes classifying the different clusters were extracted using the RefliefF algorithm95. Walking data gen-
erated from the clusters analysis were examined by principal component analysis (PCA). Principal components 
were calculated using eigenvalue decomposition on the centred and standardised dataset. The number of relevant 
principal components was determined with a Kaiser-Guttman stopping criteria.
Data availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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